Knowledge Library

Adenoassociated virus (AAV) is often the vector of choice for gene therapies due to their low immunogenicity, ability to promote long-term gene expression, and capsid tropism-dependent tissue specificity. Representing around 37% of the current advanced therapies market, there is an ongoing demand for robust quality lot release programs capable of supporting the large patient cohorts …Read More >

Adeno-associated virus (AAV) is often the vector of choice for gene therapies; in fact, AAV represents around 37% of the current advanced therapies market. And when it comes to manufacturing AAV for in vivo gene therapies, developers must pursue triplicate goals of quality, quantity, and speed. At OXGENE and WuXi ATU, our ambition is to …Read More >

The majority of adeno-associated viral (AAV) vector produced globally is manufactured using triple transfection. But plasmid-based AAV manufacture has drawbacks – the need to transfect cells results in a process which cannot be truly scalable, and yield and particle infectivity could be improved upon. Tetracycline Enabled Self Silencing Adenovirus (TESSA) technology utilizes adenovirus to manufacture …Read More >

Adenoassociated virus (AAV) is a popular choice of viral vector for new gene therapies, but manufacturing systems have not kept pace with biological advances, leaving these therapies costly, difficult to produce at scale, and subject to inherent batch-to-batch variability. In this webinar, Dr. Weiheng Su describes how rethinking AAV manufacture “from the ground up” allowed …Read More >

We are all keenly aware that viruses can negatively impact our lives, but what about viruses that shape our existence and even improve some of its outcomes? In the past several decades, advances in cell and gene therapies have exploded due to innovations with adeno-associated virus (AAV). Yet, given its small genomic size, the life …Read More >